Education
About Us
Working with TipRanks
Follow Us
Rani Therapeutics Holdings (RANI)
NASDAQ:RANI
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 8.33%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.Company Guidance
During Rani Therapeutics' fourth quarter and full year 2024 earnings call, guidance was provided on the company's strategic focus and financial outlook. The company emphasized advancements in its RaniPill platform, highlighting its application in obesity and immunology spaces. Rani plans to further develop its RT-114 and semaglutide programs, with RT-114 moving into clinical trials by mid-2025. Financially, Rani reported a net loss of $56.6 million for the full year, an improvement from $67.9 million in 2023, partly due to cost containment measures. The company ended the year with $27.6 million in cash and expects this to fund operations into the third quarter of 2025. Additionally, Rani is exploring partnership opportunities to leverage its platform technology across multiple indications.Advancements in RaniPill Technology
The RaniPill technology, designed for oral delivery of biologics, has shown success in preclinical and clinical trials, achieving high bioavailability for 19 molecules and completing three Phase 1 studies with no serious adverse events.
Progress in Obesity Treatment Pipeline
Rani made significant advancements in their obesity treatment pipeline, particularly with RT-114 and semaglutide programs, expecting the obesity market to reach $100 billion by 2030.
Successful Preclinical Data for RT-116
RT-116 demonstrated comparable pharmacokinetics and weight loss to subcutaneous administration with a relative bioavailability of 107% in preclinical studies.
RT-114 Preclinical Success
RT-114 showed higher Cmax and earlier Tmax than subcutaneous PG-102, with a relative bioavailability of 111% and equivalent weight loss in canine studies.
Strategic Partnership with ProGen
Rani entered a co-development agreement with ProGen for RT-114, combining ProGen's GLP-1/GLP-2 molecule with RaniPill technology.
RANI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RANI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $0.48 | $0.56 | +16.67% |
Mar 31, 2025 | $1.26 | $1.23 | -2.38% |
Nov 14, 2024 | $2.47 | $2.35 | -4.86% |
Aug 06, 2024 | $2.50 | $2.43 | -2.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rani Therapeutics Holdings (RANI) report earnings?
Rani Therapeutics Holdings (RANI) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Rani Therapeutics Holdings (RANI) earnings time?
Rani Therapeutics Holdings (RANI) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RANI EPS forecast?
RANI EPS forecast for the fiscal quarter 2025 (Q2) is -0.29.